In brief
Fibromyalgia is a nociplastic pain syndrome characterised by chronic widespread pain, fatigue, sleep disturbance and cognitive difficulties (fibro-fog), underpinned by sensitisation of the central nervous system. Diagnosis is clinical, based on the ACR 2016 criteria (generalised pain in at least 4 of 5 body regions, WPI and SSS) or AAPT 2019, with no biomarker; tests are used for differential diagnosis. The management recommended by EULAR 2017 places exercise as the only strength A intervention, the multicomponent approach (exercise, education, cognitive-behavioural therapy) remaining superior to each component alone. Worldwide prevalence is 2 to 4%, with a female-to-male ratio of 2 to 7 per 1.
Clinical synthesis based on the ACR 2016 and AAPT 2019 criteria, the EULAR 2017 recommendations, the concept of nociplastic pain (Lancet 2021) and post-COVID data 2024-2026.
Clinical synthesis
- Fibromyalgia is a nociplastic pain syndrome characterised by diffuse pain, fatigue, sleep disturbance and fibro-fog. The central mechanism is a sensitisation of the central nervous system (Fitzcharles 2021 Lancet).
- Worldwide prevalence is 2-4 % (Jones 2015; Heidari 2017 meta-analysis). Women are affected 2 to 7 times more often, depending on the diagnostic criteria used. Peak onset is between 30 and 50 years.
- Risk factors combine genetic predisposition (heritability ~50%, Park & Lee 2017), environmental triggers (infections, trauma, stress) and comorbidities (RA, SLE, post-COVID Ursini 2021).
- The pathophysiology combines central sensitisation, glial neuroinflammation (Ji 2018) and neurotransmitter imbalances (lower serotonin/noradrenaline, higher substance P/glutamate).
- Diagnosis is clinical, based on the ACR 2016 criteria (Wolfe: generalised pain in ≥ 4 of 5 regions + WPI + SSS) or AAPT 2019 (Arnold). No biomarker; tests are used for differential diagnosis.
- Examination rules out rheumatoid arthritis, lupus, Sjögren's, hypothyroidism, neuropathies, and considers the overlaps (TMD, IBS, ME/CFS, post-COVID).
- The phenotypes are emerging as a precision-medicine tool: subgroups with high psychological distress, high sensitisation, or adaptive (Goudman 2022; Migliorini 2025 juvenile).
- The EULAR 2017 approach (Macfarlane) recommends exercise as the only strength A intervention. The multicomponent approach (exercise + education + CBT) remains superior to each component alone (Hauser 2009).
- Exercise: aerobic (Bidonde 2017 Cochrane) and resistance (Busch 2013 Cochrane) have equivalent effects. The choice should follow preferences for long-term adherence.
- Both CBT (Bernardy 2018 Eur J Pain meta-analysis) and pain neuroscience education (Suso-Marti 2022 PNE meta) are psycho-cognitive pillars.
- Passive therapies (massage, TENS) have a level of evidence that is low ; they may modulate symptoms in the short term but do not address the underlying problem.
- Pacing (rhythm management), sleep hygiene and structured self-management are essential to avoid the boom-bust cycle and ensure lasting results.
- Differential diagnosis must include post-COVID which mimics fibromyalgia (Ursini 2021 RMD Open, cross-sectional web survey, n = 616: 30.7% of subjects meeting the ACR criteria 6 ± 3 months after COVID-19).
- Refer to a doctor, rheumatologist or psychologist when red flags (Finucane 2020) or predominant psychosocial yellow flags are present.
- Measuring progress with validated PROMs (FIQR, NPRS, PCS, PSQI) facilitates shared decision-making and therapeutic justification.
Contents
- What are the fundamentals to know about fibromyalgia?
- How do you assess and diagnose fibromyalgia with certainty?
- Phenotypes and pharmacotherapy: what do they add alongside active therapies?
- Which treatment strategies are the most effective?
- How do you secure lasting recovery and prevent flares?
- What do real clinical cases teach us about fibromyalgia?
- How do you apply these recommendations concretely in your practice?
What are the fundamentals to know about fibromyalgia?
Fibromyalgia has changed profoundly in the scientific literature: long considered an ill-defined functional disorder, it is now classified as nociplastic pain by the IASP, that is, pain resulting from an alteration of nociception without an identifiable lesion of the somatosensory system.¹ This reconceptualisation has major clinical consequences for assessment and management.
How is this condition defined, who does it affect and what are the risk factors?
Fibromyalgia is defined by four cardinal symptoms: chronic widespread pain, intense fatigue, non-restorative sleep and cognitive difficulties (the \"fibro-fog\": difficulty concentrating, working memory).² Diagnosis no longer uses the count of 18 tender points since 2010; it rests on the revised ACR criteria (Wolfe 2016) or the AAPT 2019 criteria (Arnold).³,⁴
The worldwide prevalence of fibromyalgia depends closely on the criteria used. The Heidari 2017 meta-analysis (Rheumatol Int) reports a prevalence of the order of 1.8-2.9 % in the general population with the ACR 1990 criteria, but it rises to 5.4 % with the modified 2010 criteria in the British prevalence study Jones 2015 (Arthritis Rheumatol).⁵,⁶ This variability reflects the growing sensitivity of the criteria but also a persistent methodological debate.
📊 Prevalence of fibromyalgia according to the diagnostic criteria used
Percentages from a British population survey (Jones 2015)
Source: Jones GT et al. Arthritis Rheumatol. 2015;67(2):568-575. PMID 25323744.
The female:male ratio varies greatly depending on the criteria: with ACR 1990 (which required 11 tender points out of 18), it reached 7-9:1, but it falls to 2:1 with the 2010 criteria, which remove palpation of the tender points.⁷
The risk factors are multifactorial:
- Genetics: heritability is estimated at around 50%, with strong familial aggregation (RR x8 in first-degree relatives). Polymorphisms of serotonergic (5-HTT, 5-HT2A), dopaminergic (DRD4, COMT) and catecholaminergic genes are involved (Park & Lee 2017).⁸
- Environmental triggers: physical trauma (notably whiplash), infections (Lyme, EBV, hepatitis C, COVID-19) and intense psychological stress can precipitate the syndrome.⁹
- Comorbidities: fibromyalgia coexists with rheumatoid arthritis in 18-24%, lupus in 30%, Sjögren's syndrome in 50% and axial spondyloarthritis in 14-16% of cases.⁶
- Sex: sex hormones, differences in nociceptive thresholds and X-chromosome-linked gene expression partly explain the female predominance.⁷
What happens in the body and how does fibromyalgia evolve naturally?

MRIFunctional brain MRI, axial, coronal and sagittal slices: yellow areas of increased pain-related activation in fibromyalgia patients compared with healthy subjects, reflecting central sensitisation.
Source : Pujol et al., PLoS ONE, 2009, figure 4 · CC BY
The central mechanism is central sensitisation, that is, an amplification of nociceptive signals in the CNS, expressed clinically as:¹,²
- Hyperalgesia : exaggerated response to a normally painful stimulus.
- Allodynia : pain in response to a non-painful stimulus (clothing, vibration).
- Temporal summation increased (\"wind-up\").
- Deficient descending modulation (altered conditioned pain modulation test).
These mechanisms are underpinned by several documented neurobiological alterations:
- Low-grade glial neuroinflammation : activation of microglial and astrocytic cells releasing pro-inflammatory cytokines (IL-6, TNF-alpha) and chemokines (Ji 2018 Anesthesiology). This neuroinflammation has been demonstrated on PET imaging with a translocator marker (TSPO).¹⁰
- Neurotransmitter imbalances : decreased serotonin and noradrenaline (which inhibit pain); increased substance P (x3 in the CSF) and glutamate.²
- Hyperactive HPA axis and dysautonomia: predominant sympathicotonia, loss of heart rate variability.
- Intestinal dysbiosis : recent Mendelian studies from 2023-2025 suggest a causal link between microbiota alterations and symptom severity.¹¹
The natural course is chronic and fluctuating. The prospective study by Walitt 2011 of 1,555 patients followed for 11 years in the NDB cohort showed that symptom severity remains globally stable, with only 25% showing significant improvement and fewer than 10% complete remission.¹² Poor prognostic factors include: severe symptoms at diagnosis, psychiatric comorbidities, low physical activity, catastrophising and low self-efficacy.¹³
- Fibromyalgia is now classified as nociplastic pain (Fitzcharles 2021 Lancet), reflecting documented central sensitisation.
- The prevalence is 2 to 4% (up to 5.4% with the modified 2010 criteria), with a female:male ratio of 2-7:1 depending on the criteria.
- The risk factors combine heritability (~50%), triggers (infections, traumas, stress) and comorbidities (RA 18-24%, SLE 30%).
- The mechanisms include hyperalgesia + allodynia + glial neuroinflammation + serotonin/substance P imbalances.
- The course is chronic and fluctuating ; complete remission is rare and requires active multimodal management.
Bibliography chapter 1
- Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Hauser W. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397(10289):2098-2110. PMID 34062144
- Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16(11):645-660. PMID 33024295
- Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319-329. PMID 27916278
- Arnold LM, Bennett RM, Crofford LJ, et al. AAPT Diagnostic Criteria for Fibromyalgia. J Pain. 2019;20(6):611-628. PMID 30453109
- Heidari F, Afshari M, Moosazadeh M. Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis. Rheumatol Int. 2017;37(9):1527-1539. PMID 28447207.
- Jones GT, Atzeni F, Beasley M, et al. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol. 2015;67(2):568-575. PMID 25323744
- Hauser W, Ablin J, Fitzcharles MA, et al. Fibromyalgia. Nat Rev Dis Primers. 2015;1:15022. PMID 27189527
- Park DJ, Lee SS. New insights into the genetics of fibromyalgia. Korean J Intern Med. 2017;32(6):984-995. PMID 29056037
- Ursini F, Ciaffi J, Mancarella L, et al. Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey. RMD Open. 2021;7(3):e001735. PMID 34426540
- Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and Central Sensitization in Chronic and Widespread Pain. Anesthesiology. 2018;129(2):343-366. PMID 29462012
- Minerbi A, Fitzcharles MA. Gut microbiome: pertinence in fibromyalgia. Clin Exp Rheumatol. 2020;38 Suppl 123(1):99-104. PMID 32116215.
- Walitt B, Fitzcharles MA, Hassett AL, Katz RS, Hauser W, Wolfe F. The longitudinal outcome of fibromyalgia: a study of 1555 patients. J Rheumatol. 2011;38(10):2238-2246. PMID 21765102
- Galvez-Sanchez CM, Reyes Del Paso GA. Diagnostic Criteria for Fibromyalgia: Critical Review and Future Perspectives. J Clin Med. 2020;9(4):1219. PMID 32340369
How do you assess and diagnose fibromyalgia with certainty?
Which questions should you ask to understand the patient and their history?
History-taking is the cornerstone of diagnosis. It must explore five key dimensions:¹,²
- Description and topography of the pain : marking on a body chart the 19 areas of the Widespread Pain Index (WPI) (shoulder L/R, hip L/R, thigh L/R, lower leg L/R, jaw L/R, upper arm L/R, forearm L/R, chest, upper back, lower back, neck, abdomen). Key question: \"Over the past week, in how many areas have you had pain?\"³
- Severity of associated symptoms : assessment of fatigue, non-restorative sleep and cognitive difficulties on a 0-3 scale (Symptom Severity Scale - SSS). To this is added the presence/absence over the last 6 months of headaches, lower abdominal pain and depression (possible total 0-12).³
- Chronology and triggers : duration of symptoms (the criterion requires ≥ 3 months at a similar level), potential trigger (infection, trauma, surgery, stress), fluctuating course.
- Functional impact : impact on work, social life, sleep, daily activities. The Fibromyalgia Impact Questionnaire Revised (FIQR) is the reference tool (0-100, MCID ≈ 14 points).⁴
- Treatment history : drug and non-drug treatments tried, perceived response, adverse effects.
The question of the beliefs and representations of the patient about their pain is crucial: kinesiophobia, catastrophising and external locus of control predict a poorer response to active interventions.⁵
Which clinical tests should be performed and which other conditions need to be ruled out?
Positive diagnosis rests on the ACR 2016 criteria (Wolfe), which require three conditions met simultaneously:³
| Criterion | Operational definition | Threshold for diagnosis |
|---|---|---|
| Generalised pain | Pain present in at least 4 of the 5 body regions (upper right, upper left, lower right, lower left, axial); jaw, chest and abdomen do not count in this tally | ≥ 4 of 5 regions |
| WPI | Number of painful areas out of the 19 listed | ≥ 7 AND SSS ≥ 5 OR 4-6 AND SSS ≥ 9 |
| SSS | Severity (0-3 each): fatigue + sleep + cognition + 3 somatic symptoms (0-3) | See above |
| Duration | Symptoms present at a similar level | ≥ 3 months |
| Other diagnoses | No longer exclude fibromyalgia (since 2016) | May coexist |
The AAPT 2019 criteria (Arnold) are a simpler alternative validated by the IASP-American Pain Society:⁴
- Widespread pain affecting ≥ 6 of 9 sites (head, arms L/R, chest, abdomen, upper back, lower back, legs L/R).
- Non-restorative sleep OR fatigue (at least moderate).
- Symptoms present for ≥ 3 months.
📊 Diagnostic decision flow for fibromyalgia (ACR 2016)
Decision tree combining generalised pain, WPI, SSS and duration
Adapted from Wolfe F et al. Semin Arthritis Rheum. 2016;46(3):319-329. PMID 27916278.
Physical examination remains useful to exclude organic conditions. Look for: inflammatory joint signs (swelling, redness), neurological deficits (strength, sensation, reflexes), cardiac murmurs, lymphadenopathy, thyroid signs. Palpation may reveal diffuse hyperalgesia (a sign of central sensitisation) but is no longer required for diagnosis.³
Red flags requiring further investigation
- Overt inflammatory symptoms : morning stiffness > 60 min, visible joint swelling → rheumatologist (RA, SpA, SLE).
- Fatigue + unexplained weight loss + night sweats → oncological work-up / lymphoma.
- Objective muscle weakness → neurological work-up (myositis, neuropathy, multiple sclerosis).
- Multisystem involvement (skin, eyes, kidneys) → rheumato-immunological work-up.
- Sudden onset after age 60 → always suspect an underlying organic condition before fibromyalgia.
- Endocrine signs (cold intolerance, dry skin) → TSH, free T4.
The minimum laboratory work-up recommended by EULAR for differential diagnosis includes:⁸
- FBC, ESR, CRP (to exclude systemic inflammation)
- TSH (to exclude hypothyroidism)
- CPK (creatine phosphokinase; excludes myopathy)
- Vitamin D (frequent deficiency, may worsen muscular symptoms)
- Ferritin (iron deficiency is common in women)
- Serum calcium, fasting blood glucose
Routine imaging has no place in the positive diagnosis of fibromyalgia. It is reserved for red flags or a specific clinical target.⁷
Main differential diagnosis:
- Rheumatoid arthritis : symmetrical arthritis, RF/anti-CCP, raised ESR/CRP.
- Systemic lupus : SLICC criteria, ANA, anti-DNA, skin/renal involvement.
- Sjögren's : sicca syndrome, anti-SSA/SSB, salivary gland biopsy.
- Hypothyroidism : raised TSH, low T4, endocrine signs.
- Polymyalgia rheumatica : age > 50, girdle pain, ESR > 50.
- Axial spondyloarthritis : inflammatory back pain, HLA-B27, sacroiliac MRI.
- Chronic fatigue syndrome / ME-CFS : prolonged post-exertional malaise.
- Vitamin D deficiency and iron deficiency.
- Adverse drug effects (statins, aromatase inhibitors).
- The diagnosis of fibromyalgia is clinical, based on ACR 2016 (generalised pain in ≥ 4 of 5 regions; WPI + SSS; ≥ 3 months) or AAPT 2019 (pain at ≥ 6/9 sites + fatigue/sleep + ≥ 3 months).
- Since 2016, fibromyalgia can coexist with other conditions (it is no longer a strict diagnosis of exclusion).
- The laboratory tests are used for differential diagnosis: FBC, ESR/CRP, TSH, CK, vit D, ferritin.
- Imaging has no place in positive diagnosis.
- Red flags (inflammation, weight loss, objective weakness) require rapid referral to exclude serious pathology.
Bibliography chapter 2
- Arnold LM, Bennett RM, Crofford LJ, et al. AAPT Diagnostic Criteria for Fibromyalgia. J Pain. 2019;20(6):611-628. PMID 30453109
- Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. PMID 27377815
- Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319-329. PMID 27916278
- Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11(4):R120. PMID 19664287
- Galvez-Sanchez CM, Reyes Del Paso GA. Diagnostic Criteria for Fibromyalgia: Critical Review and Future Perspectives. J Clin Med. 2020;9(4):1219. PMID 32340369
- Winslow BT, Vandal C, Dang L. Fibromyalgia: Diagnosis and Management. Am Fam Physician. 2023;107(2):137-144. PMID 36791450
- Hauser W, Ablin J, Fitzcharles MA, et al. Fibromyalgia. Nat Rev Dis Primers. 2015;1:15022. PMID 27189527
- Hauser W, Perrot S, Sommer C, Shir Y, Fitzcharles MA. Diagnostic confounders of chronic widespread pain: not always fibromyalgia. Pain Rep. 2017;2(3):e598. PMID 29392213
Phenotypes and pharmacotherapy: what do they add alongside active therapies?
How do you classify patients into clinically useful subgroups?
The great heterogeneity of fibromyalgia patients partly explains why meta-analyses show moderate clinical effects: an \"overloaded\" patient with extreme catastrophising will not respond like an \"adaptive\" patient with low distress. The effort of phenotyping or profiling aims to personalise interventions.¹
Several cluster analysis studies (Vincent 2014, de Souza 2009, Yim 2017) converge on 3 to 4 recurring subgroups :²,³
| Phenotype | Dominant characteristics | Preferred therapeutic strategy |
|---|---|---|
| Adaptive (~20-25 %) | Mild to moderate symptoms, low distress, relatively preserved function | Education + self-managed exercise |
| High sensitisation (~30 %) | Marked hyperalgesia, allodynia, temporal summation, high pain scores | Pain education + very gradual exercise + consider neuromodulation (duloxetine, pregabalin) |
| High psychological distress (~25-30 %) | Catastrophising, depression, anxiety, history of trauma, kinesiophobia | CBT as a priority + ACT/MBSR + gradual exercise |
| Severe multifactorial (~15-20 %) | FIQR score > 70, multiple comorbidities, major functional impact | Intensive interdisciplinary management (rheumatology + physiotherapy + psychology + pharmacotherapy) |
The Migliorini 2025 study (Med Sci, level I) on juvenile fibromyalgia suggests a similar stratification in paediatrics, with particular efficacy of cognitive-behavioural approaches in adolescents with high distress.⁴
The Brazilian SR 2025 review (parts I & II) confirms the clinical usefulness of phenotyping and proposes a decision algorithm based on the FIQR score and the clinical subtype.⁵,⁶
What is the place of medication in fibromyalgia?
The EULAR 2017 recommendations are clear: no drug is first-line. Pharmacology has a role as an adjunct to facilitate engagement in active therapies (exercise, CBT) when pain, sleep or mood are too impaired.⁷
Three drugs are approved by the FDA for fibromyalgia in the United States (not in France or Europe): duloxetine, milnacipran and pregabalin.⁸ None is specifically approved for this indication in Europe.
The 2023 Cochrane network meta-analysis of antidepressants (176 trials, all chronic pain conditions combined, including 59 in fibromyalgia): its authors state they are certain only about duloxetine (moderate to high certainty, small to moderate effect); milnacipran, often ranked just after, is judged promising, with lower certainty (moderate on some secondary outcomes, with small effects), and the evidence remains of low certainty for the other antidepressants in the review. No reliable evidence exists on long-term efficacy (the trials lasted 10 weeks on average) or on safety.¹⁰
📊 Level of evidence of the main pharmacological options
Effects on pain, sleep and quality of life
Synthesis: Sarzi-Puttini 2020 Nat Rev Rheumatol; Brazilian SR 2025 parts I-II; Hauser 2019 Cochrane reviews overview; Birkinshaw 2023 Cochrane (network meta-analysis of antidepressants, all chronic pain conditions).
Prescribing principles:
- Start low, increase slowly (\"start low, go slow\") because fibromyalgia patients are sensitive to adverse effects.
- Reassess at 8-12 weeks : if there is no noticeable benefit, stop and do not accumulate treatments.
- Strictly avoid strong opioids (morphine, oxycodone): no demonstrated benefit, risk of dependence and opioid-induced hyperalgesia.⁷,⁸
- Tramadol : a weak option if others fail, but risk of serotonin syndrome with SNRI.
- NSAIDs and paracetamol : of little effectiveness as monotherapy for fibromyalgic pain (nociplastic, non-inflammatory).
- Corticosteroids : no place.
- Cannabinoids : emerging evidence (Sarzi-Puttini 2020), notably nabilone for sleep; they remain tightly regulated in France.
The stepped care approach proposes a rational escalation:⁹
- Step 1: Education + exercise + self-management (8-12 weeks)
- Step 2: If it fails, add CBT + consider low-dose amitriptyline (10-25 mg/evening)
- Step 3: If failure persists and FIQR > 60, consider duloxetine or milnacipran or pregabalin (12-week trial)
- Step 4: Intensive interdisciplinary management in a pain centre
- Fibromyalgia is heterogeneous : phenotyping into 3-4 subgroups (adaptive, sensitisation, distress, severe) allows more personalised medicine.
- No drug is first-line ; they are adjuncts to enable engagement in exercise and CBT.
- Modest effect of duloxetine, pregabalin and milnacipran (NNT ≈ 8-10); among antidepressants, duloxetine is the only one the authors of the 2023 Cochrane review say they are certain about, all chronic pain conditions combined.
- Low-dose amitriptyline is sometimes proposed for sleep; its evidence is of low certainty.
- Strong opioids to be avoided ; tramadol as a last resort only.
- The stepped care approach avoids unnecessary pharmacological escalation and favours active therapies.
Bibliography chapter 3
- Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16(11):645-660. PMID 33024295
- Vincent A, Hoskin TL, Whipple MO, et al. OMERACT-based fibromyalgia symptom subgroups: an exploratory cluster analysis. Arthritis Res Ther. 2014;16(5):463. PMID 25318839
- Yim YR, Lee KE, Park DJ, et al. Identifying fibromyalgia subgroups using cluster analysis: Relationships with clinical variables. Eur J Pain. 2017;21(2):374-384. PMID 27633925
- Migliorini F, Maffulli N, Memminger MK, et al. Management of Juvenile Fibromyalgia: A Level I Evidence-Based Systematic Review. Med Sci (Basel). 2025;13(3). PMID 41003152.
- Heymann RE, Rezende MC, Braz AS, et al. Brazilian Society of Rheumatology's fibromyalgia treatment guidelines - part I: monitoring and non-pharmacological management. Adv Rheumatol. 2026;66(1):10. PMID 41546125
- Heymann RE, et al. Review of fibromyalgia treatment guidelines: part 2 - pharmacological treatment. Adv Rheumatol. 2026. PMID 41572407
- Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. PMID 27377815
- Welsch P, Üçeyler N, Klose P, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018;2(2):CD010292. PMID 29489029.
- Hauser W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther. 2014;16(1):201. PMID 24433463
- Birkinshaw H, Friedrich CM, Cole P, et al. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Cochrane Database Syst Rev. 2023;5(5):CD014682. PMID 37160297.
What are the most effective treatment strategies for fibromyalgia?
Where do you start? What is the recommended hierarchy of interventions?
The EULAR 2017 recommendations marked a turning point by placing physical exercise as the only intervention with a strong recommendation for all fibromyalgia patients.¹ The other interventions are \"weak for\" or \"weak against\" depending on the benefit-risk-cost ratio.
📊 Hierarchy of interventions by level of evidence (EULAR 2017)
Pyramid in horizontal cards with level of recommendation
Ranked EULAR 2017 recommendations - the horizontal cards avoid the unreadable text of triangular pyramids.
The most effective approach is multimodal. The Hauser 2009 meta-analysis (Arthritis Care Res) of 9 RCTs showed that the combination exercise + education + CBT is superior to each component alone, with effects lasting 1 year for pain, fatigue and mood.²
Practical hierarchy:
- Foundation: therapeutic patient education (TPE); explanation of nociplastic mechanisms; therapeutic alliance.
- Central pillar: individualised, progressive exercise programme, based on the patient's preferences, on land or in a pool.
- Psychological support: CBT, ACT, MBSR depending on profile and acceptability.
- Adjuncts: passive balneotherapy (hot bath without an exercise programme), pharmacological neuromodulation if failure, occasional passive therapies during a flare. Pool exercise falls under the central pillar.
What is the place of exercise and is one approach superior?
Exercise is the only intervention to receive a strong recommendation from EULAR 2017, on the basis of meta-analyses.¹ Successive Cochrane meta-analyses confirm significant effects on pain (SMD ~ -0.5), function (SMD ~ -0.6) and quality of life.³,⁴
There is no clear evidence of superiority of one type of exercise over another; the choice should follow preferences to ensure adherence:⁵
| Modality | Effect on pain | Effect on function | Effect on quality of life | Level of evidence |
|---|---|---|---|---|
| Aerobic (walking, cycling, swimming) | SMD -0.46 | SMD -0.69 | SMD -0.76 | 1A Cochrane (Bidonde 2017) |
| Resistance (progressive strength training) | 3.3 cm/10 VAS | FIQ -16.75 pts | + quality of life | 1A Cochrane (Busch 2013) |
| Aquatic | SMD -0.40 | + stiffness | SMD -0.52 | 1B (Bidonde 2014) |
| Tai Chi | SMD -0.88 | FIQ -6.21 pts | + sleep | 1B RCT (Wang 2018 BMJ) |
| Yoga / pilates | SMD -0.4 to -0.6 | + flexibility | + moderate | 2A (Sosa-Reina 2017) |
| Mixed / combined | SMD -0.55 | SMD -0.65 | + optimal | 1A (Andrade 2022) |
Two network meta-analyses published in 2025 place aquatic exercise among the most effective modalities for pain: first in the short term in one, conducted in women, with moderate certainty according to its authors, who judge, however, that only strengthening stands out in a clinically relevant way from usual care and sham, in the short term as in the long term¹⁶; second in the other, behind aerobic exercise combined with flexibility, with low to very low certainty.¹⁷ A third, focused on sleep and of low certainty, cites aerobic exercise in an aquatic setting among the forms of exercise that could improve it, without making it the only one.¹⁸ Rankings vary from one review to the other, and the reviews may share trials. The authors of the second give, to reach the minimal clinically important difference on pain, a benchmark of about 875 MET-minutes per week, or perhaps 2 to 3 sessions, as an indication for the clinician and not as a prescription, starting at low intensity.¹⁷
The key principle is \"Start Low, Go Slow\" : start well below the patient's perceived limits, gradually increase a single parameter at a time (frequency, duration, intensity).⁶ A pragmatic rule: if pain increases by more than 2 points on the VAS for 48h after the session, reduce the load by 25%.
Typical beginner programme (Bidonde 2017 / Busch 2013 adapted):
- Phase 1 (weeks 1-4): 20 min gentle walking 3x/week + 15 min global mobility + breathing. No more than 50% of maximum heart rate.
- Phase 2 (weeks 5-8): add low-load segmental strengthening (50% 1RM, 8-12 reps, 2 sets, 2x/week).
- Phase 3 (weeks 9-12): progressively intensify walking or cycling (up to 30-40 min) + progressive strengthening.
- Phase 4 (3+ months): find an enjoyable activity for independent maintenance.
Manual therapies and technology: how effective are they really?
Passive therapies have a limited place, often requested by patients hoping for an external solution but with weak evidence of lasting efficacy.⁷
- Therapeutic massage : short-term effect on pain and anxiety (Yuan 2015 meta-analysis, moderate NNT), but the effect is not maintained beyond 6 weeks. Useful as an adjunct to open up engagement in exercise.⁸
- Mobilisations / manipulations : very weak evidence. Not recommended as a core practice but may relieve associated cervico-thoracic tension points.
- Balneotherapy / hot hydrotherapy : beneficial short-term effects on pain and quality of life (Nuesch 2013 Ann Rheum Dis NMA), probably multifactorial (heat, buoyancy, gentle exercise, relaxation).⁹
- TENS, ultrasound, laser, shock waves : limited and heterogeneous evidence. The Salazar 2017 review concludes that there is insufficient evidence to recommend electrical stimulation routinely.¹⁰
- Acupuncture : moderate short-term effects (Deare 2013 Cochrane). Less effective than exercise but may be a preferred option for some patients.
- rTMS (transcranial magnetic stimulation) : emerging evidence, mainly on the motor cortex. Remains experimental in the clinic.
These modalities should be considered as temporary adjuncts allowing symptom modulation to facilitate engagement in active strategies.¹,⁷
Beyond the physical: how do you educate the patient and address psychological factors?
Pain neuroscience education (PNE) has become a standard. It aims to deconstruct mistaken beliefs (\"I have damaged muscles\", \"the more it hurts, the more serious it is\") and to reconceptualise pain as an experience modulated by the brain rather than a pure signal of injury.¹² The Suso-Marti 2022 meta-analysis (Pain Med) of 8 RCTs shows significant moderate effects on pain (SMD -0.5) and impact (SMD -0.7) with low quality of evidence.¹³
The Cognitive-Behavioural Therapy (CBT) is the most studied psychological approach. The Bernardy 2018 meta-analysis (Eur J Pain, 23 RCTs, 2,031 patients) confirms significant but moderate effects on:¹⁴
- Pain (SMD -0.32; 95% CI -0.49 to -0.15)
- Depressive mood (SMD -0.33)
- Functional capacity (SMD -0.32)
- No significant effect on fatigue or on isolated sleep
The acceptance and commitment therapy (ACT) and mindfulness-based stress reduction (MBSR) are effective alternatives (Veehof 2016) with results comparable to conventional CBT, sometimes better accepted by patients who are refractory to a \"cognitive\" approach.¹⁵
📊 Mean effects (SMD) of active interventions on pain
Synthesis of recent meta-analyses - negative values = pain reduction
Sources: Bidonde 2017 Cochrane; Busch 2013 Cochrane; Wang 2018 BMJ tai chi RCT; Bernardy 2018 Eur J Pain CBT; Suso-Marti 2022 Pain Med PNE; Yuan 2015 manual therapies meta-analysis.
The caveats to bear in mind: even statistically significant effects are moderate in practice (Δ ~ 1-1.5 point/10 VAS), sometimes below the threshold of the minimal clinically important difference (MCID). Individual response is highly heterogeneous; some patients are \"super-responders\", others derive no benefit. This strengthens the argument for phenotyping.⁴,¹⁵
Indications for referral for psychological support
- PCS score (Pain Catastrophizing Scale) > 30 (severe catastrophising)
- PHQ-9 > 15 (moderate-severe depression)
- GAD-7 > 15 (severe anxiety)
- History of untreated psychological trauma (high ACE score)
- Suicidal ideation (systematic screening: rate 2-3x higher in FM)
- Failure to engage in active therapies after 8-12 weeks
- EULAR 2017: exercise = only strong recommendation. Aerobic or resistance are equivalent; choice according to preferences.
- The multicomponent approach (exercise + education + CBT) is superior to each component alone.
- Pain neuroscience education (PNE) and CBT have moderate but significant effects.
- The passive therapies (massage, TENS, manipulations) are temporary adjuncts; no underlying therapeutic effect.
- Principle \"Start Low, Go Slow\" to avoid pain flare-ups; monitor PCS, PHQ-9, GAD-7.
Bibliography chapter 4
- Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. PMID 27377815
- Hauser W, Bernardy K, Arnold B, Offenbacher M, Schiltenwolf M. Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Arthritis Rheum. 2009;61(2):216-224. PMID 19177530
- Bidonde J, Busch AJ, Schachter CL, et al. Aerobic exercise training for adults with fibromyalgia. Cochrane Database Syst Rev. 2017;6(6):CD012700. PMID 28636204
- Busch AJ, Webber SC, Richards RS, et al. Resistance exercise training for fibromyalgia. Cochrane Database Syst Rev. 2013;(12):CD010884. PMID 24362925
- Sosa-Reina MD, Núñez-Nagy S, Gallego-Izquierdo T, et al. Effectiveness of Therapeutic Exercise in Fibromyalgia Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Biomed Res Int. 2017;2017:2356346. PMID 29291206
- Albuquerque MLL, Monteiro D, Marinho DA, et al. Effects of different protocols of physical exercise on fibromyalgia syndrome treatment: systematic review and meta-analysis of randomized controlled trials. Rheumatol Int. 2022;42(11):1893-1908. PMID 35604435.
- Wang C, Schmid CH, Fielding RA, et al. Effect of tai chi versus aerobic exercise for fibromyalgia: comparative effectiveness randomized controlled trial. BMJ. 2018;360:k851. PMID 29563100
- Yuan SLK, Matsutani LA, Marqués AP. Effectiveness of different styles of massage therapy in fibromyalgia: a systematic review and meta-analysis. Man Ther. 2015;20(2):257-264. PMID 25457196
- Nuesch E, Hauser W, Bernardy K, Barth J, Juni P. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis. 2013;72(6):955-962. PMID 22739992
- Salazar AP, Stein C, Marchese RR, et al. Electric Stimulation for Pain Relief in Patients with Fibromyalgia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Pain Physician. 2017;20(2):15-25. PMID 28158150.
- Deare JC, Zheng Z, Xue CC, et al. Acupuncture for treating fibromyalgia. Cochrane Database Syst Rev. 2013;(5):CD007070. PMID 23728665
- Moseley GL, Butler DS. Fifteen Years of Explaining Pain: The Past, Present, and Future. J Pain. 2015;16(9):807-813. PMID 26051220
- Suso-Marti L, Cuenca-Martínez F, Alba-Quesada P, et al. Effectiveness of Pain Neuroscience Education in Patients with Fibromyalgia: A Systematic Review and Meta-Analysis. Pain Med. 2022;23(11):1837-1850. PMID 35587171
- Bernardy K, Klose P, Welsch P, Hauser W. Efficacy, acceptability and safety of cognitive behavioural therapies in fibromyalgia syndrome - A systematic review and meta-analysis of randomized controlled trials. Eur J Pain. 2018;22(2):242-260. PMID 28984402
- Veehof MM, Trompetter HR, Bohlmeijer ET, Schreurs KMG. Acceptance- and mindfulness-based interventions for the treatment of chronic pain: a meta-analytic review. Cogn Behav Ther. 2016;45(1):5-31. PMID 26818413
- Rodríguez-Domínguez ÁJ, Rebollo-Salas M, Chillón-Martínez R, et al. The most effective therapeutic exercises for pain intensity in women with fibromyalgia: A systematic review and network meta-analysis. Braz J Phys Ther. 2025;29(4):101226. PMID 40319533.
- Wang C, Sun J, Liang Z, et al. Comparative Effectiveness of Exercise Modalities for Fibromyalgia: A Systematic Review and Bayesian Network Meta-Analysis. Eur J Pain. 2025;29(9):e70109. PMID 40888752.
- Hudson J, Imamura M, Robertson C, et al. Effects of Pharmacologic and Nonpharmacologic Interventions for the Management of Sleep Problems in People With Fibromyalgia: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Arthritis Care Res (Hoboken). 2025;77(9):1095-1105. PMID 39930945.
How do you secure lasting recovery and prevent flares?
How do you make the patient an active partner in their own recovery through self-management?
Autonomous management (self-management) is the component that ensures long-term benefits. It integrates 4 pillars:¹
- Structured therapeutic education : 4 to 8 sessions covering pathophysiology, triggers, coping strategies. Individual or group format; the group format showed an additional benefit through the effect of social support (Brazilian SR 2025).²
- Pacing (rhythm management) : balance activity and rest to avoid the \"boom-bust\" cycle (overuse followed by exhaustion and a pain flare-up). Practical tool: the \"50%\" rule - on a good day, do not exceed 50% of perceived capacity, in order to keep a reserve for more difficult days.
- Sleep hygiene : regular schedules, limiting screens 1h before bedtime, avoiding caffeine after 2 pm, 4-7-8 breathing technique. Using amitriptyline 10-25 mg in case of insomnia can facilitate this phase.
- Stress management : relaxation techniques, mindfulness meditation, a stress diary identifying personal triggers.
Self-efficacy (perception of one's own ability to control the disease) is a key mediator of outcomes. The systematic review by Geraghty et al. (2021, 39 trials) on self-management interventions finds, compared with usual care or no treatment, a gain in physical function that is maintained beyond 6 months (SMD +0.36; 95% CI 0.20 to 0.53) and a reduction in pain at the same time point (SMD -0.38; 95% CI -0.58 to -0.19), with low certainty of evidence.³
When and how do you plan a safe return to sport and activities?
The return to physical and social activities must be methodically planned to avoid relapses. The principles:⁴
- Choose an enjoyable activity : walking, gentle cycling, swimming, tai chi, dance, gentle yoga. The goal is lasting adherence, not physiological optimisation.
- Mathematical progression : increase a single parameter at a time (frequency OR duration OR intensity). 10% rule: do not increase by more than 10% per week.
- Activity diary : record activity, duration, perceived intensity, pain on the same day and the next day. Helps identify thresholds.
- Flare management : do not stop completely; temporarily reduce by 25-50% and resume progression after 3-5 days.
- Progression criterion : do not move up a level until the patient tolerates the current level without aggravation 48h later.
Beyond physical activity, social and occupational return is essential:
- Gradual return to work : consider temporary therapeutic part-time working; ergonomic adjustments (regular breaks, alternating sitting/standing position, suitable lighting).
- Support networks : patient associations (in France: FibromyalgieSOS, Association Francaise de la Fibromyalgie); avoid the social isolation that worsens catastrophising and depression.
- Engagement in rewarding activities : even moderate, they strengthen the sense of efficacy and reduce the image of a \"chronically ill person\".
📊 Typical 6-month progression of return to activity
\"Start low, go slow\" model with flare management
Conceptual diagram - flares are expected; reduce by 25-50% and resume progression after stabilisation.
Progress indicators to track (in addition to the FIQR):
- Number of steps per day (progressive goal: +500/week up to 6,000-8,000)
- PSQI score (sleep quality)
- PCS score (catastrophising) - should decrease
- Self-efficacy (Lorig scale)
- Movement tolerance (movement-pose)
- Resumption of rewarding activities (social, family, occupational)
- Structured self-management (education + pacing + sleep + stress management) is the key to long-term outcomes.
- Progression respects the rule of 10%/week on a single parameter at a time.
- The flare-ups are expected ; do not stop but temporarily reduce by 25-50%.
- Track PROMs (FIQR, PSQI, PCS) and functional indicators (steps, tolerance) every 4-8 weeks.
- The social and occupational return strengthens the benefits; favour gradual adjustments.
Bibliography chapter 5
- Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. PMID 27377815
- Heymann RE, Rezende MC, Braz AS, et al. Brazilian Society of Rheumatology's fibromyalgia treatment guidelines - part I: monitoring and non-pharmacological management. Adv Rheumatol. 2026;66(1):10. PMID 41546125
- Geraghty AWA, Maund E, Newell D, et al. Self-management for chronic widespread pain including fibromyalgia: A systematic review and meta-analysis. PLoS One. 2021;16(7):e0254642. PMID 34270606.
- Albuquerque MLL, Monteiro D, Marinho DA, et al. Effects of different protocols of physical exercise on fibromyalgia syndrome treatment: systematic review and meta-analysis of randomized controlled trials. Rheumatol Int. 2022;42(11):1893-1908. PMID 35604435.
- Bidonde J, Busch AJ, Schachter CL, et al. Aerobic exercise training for adults with fibromyalgia. Cochrane Database Syst Rev. 2017;6(6):CD012700. PMID 28636204
- Bennett RM, Friend R, Jones KD, et al. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11(4):R120. PMID 19664287
- Vincent A, Whipple MO, Rhudy LM. Fibromyalgia Flares: A Qualitative Analysis. Pain Med. 2016;17(3):463-468. PMID 25586303.
What do real clinical cases teach us about fibromyalgia?
Analysis of a \"classic\" case: from assessment to resolution.
This case illustrates an effective multimodal management trajectory. A 45-year-old woman, diagnosed 10 years ago, initial assessment:
- Pain : 7/10 VAS, widespread distribution (shoulders, back, hips, legs)
- Associated symptoms : disabling fatigue (7/10), non-restorative sleep, fibro-fog affecting work
- Initial FIQR : 72/100 (severe impact)
- PCS : 38 (severe catastrophising)
- ACR 2016 criteria : WPI 12, SSS 10 → diagnosis confirmed
- Laboratory tests : normal (FBC, ESR, CRP, TSH, CPK, ferritin)
Interdisciplinary management over 12 weeks:
- Therapeutic education (4 sessions of 90 min) covering: nociplastic pathophysiology, deconstruction of mistaken beliefs, principles of pacing, sleep hygiene.
- Individualised exercise programme : progressive walking (from 10 to 30 min, 3x/wk) + low-load segmental strengthening (20% 1RM rising to 50%) + 1 weekly hot-water hydrotherapy session.
- CBT in a group (12 weekly sessions) targeting catastrophising, kinesiophobia, cognitive restructuring, stress management techniques.
- Pharmacological adjunct : amitriptyline 10 mg/evening for insomnia (first 3 weeks), gradual discontinuation.
Results at 12 weeks:
The patient maintained her programme at 6 months (without supervised sessions) with stabilisation of gains. This case illustrates that even after 10 years of progression, a structured approach can transform the trajectory.
The diagnostic challenge: when fibromyalgia mimics another condition.
Differential diagnosis is crucial because FM symptoms overlap with those of many conditions. Two situations deserve particular attention:
Case 1: Post-COVID fibromyalgia. A cross-sectional web survey conducted by Ursini 2021 (RMD Open) questioned 616 subjects who had recovered from COVID-19 (77.4% women, mean age 45 years) on average 6 ± 3 months after diagnosis: 189 of them, or 30.7 %, met the ACR criteria for fibromyalgia, often without any previous history of pain.¹ The strongest predictors were male sex (OR 9.95) and obesity (OR 41.20). As the design was cross-sectional, it describes prevalence at one point in time and provides neither longitudinal follow-up nor a prospective risk ratio. These observations blur the boundary between long COVID and fibromyalgia and suggest shared pathophysiological mechanisms (neuroinflammation, dysautonomia).
Case 2: Overlap with hypermobile Ehlers-Danlos syndrome (hEDS). Several cohort studies (notably Tinkle 2020) report frequent comorbidity: up to 40-80% of hEDS patients also meet the FM criteria. The typical presentation: widespread pain, fatigue, but with generalised hypermobility (Beighton score ≥ 5/9), hyperextensible skin and a family history. The risk is making an isolated diagnosis of FM and missing hEDS, which changes management (specific strengthening for joint stability, prevention of subluxations). The current nomenclature and the dosing of exercise in this context are covered in the article on joint hypermobility syndromes.
Differential diagnoses and overlaps to screen for systematically
- Long COVID : If onset after infection, screen for cardio-respiratory sequelae (POTS, exertional dyspnoea)
- Hypermobile Ehlers-Danlos syndrome : Beighton score, family history, skin, subluxations
- Polymyalgia rheumatica : Age > 50, ESR > 50, girdle pain
- Hypothyroidism : systematic TSH at diagnosis
- Severe vitamin D deficiency : 25-OH vit D < 12 ng/mL
- Statins / aromatase inhibitors : iatrogenic musculoskeletal effects
- Early axial spondyloarthritis : inflammatory back pain, HLA-B27, MRI
- Isolated major depressive disorder : PHQ-9 screening, personal history
Study of a complex case and syndromic overlaps.
Fibromyalgia is rarely isolated. A study by Vincent 2013 of 502 Mayo Clinic patients shows that 89% have at least one other chronic condition, most often:²
- Irritable bowel syndrome (IBS): 30-70%
- Migraine / tension-type headache: 35-55%
- Major depressive disorder: 30-40%
- Generalised anxiety disorder: 25-35%
- Temporomandibular disorders (TMD): 20-35%
- Chronic fatigue syndrome (ME-CFS): 20-50%
- Interstitial cystitis: 5-15%
- Vulvodynia: 5-15%
A multidisciplinary approach is imperative. Illustrative case : 38-year-old woman with severe FM (FIQR 80), associated IBS, history of early psychological trauma (ACE score 6/10), untreated PTSD. A purely physical approach (physiotherapy alone) is doomed to fail here; collaboration with a psychiatrist/psychotherapist (EMDR or trauma-focused therapy) is essential to unlock the trajectory.³ After 18 months of integrated management, FIQR reduced to 45, IBS stabilised, function partially restored.
Other case studies explore the potential role of fascial dysfunction in some patients (Liptan 2010, Stecco 2018): associated local myofascial pain, palpable fascial mobility restrictions. Although the level of evidence remains low, targeted fascial manual therapy may be useful in patients with a marked peripheral component, as an adjunct to the central approach.⁴ The distinction between the two presentations, and what palpation of trigger points is really worth, are detailed in the article on myofascial pain syndrome.
Critique and controversy
The persistent absence of a diagnostic biomarker fuels medical scepticism. This lack of visible objectification still explains the stigmatisation of patients and the average diagnostic odyssey of 5 years before a diagnosis is made. However, advances in functional imaging (TSPO PET, fMRI), plasma metabolomics and molecular biology converge: FM is a measurable pathophysiological reality, simply not yet by a routine blood test.⁵,⁶
The great heterogeneity of phenotypes fuels the debate: is FM a single disease or a \"nociplastic spectrum\" encompassing several subtypes? The current consensus (Fitzcharles 2021 Lancet) argues for a spectrum, which justifies the effort of phenotyping and individualisation of treatments.
- Clinical cases confirm the effectiveness of a 12-week multimodal management even after years of progression.
- The post-COVID can mimic or trigger FM (30.7% of ACR criteria met at 6 ± 3 months, Ursini 2021); screen carefully for cardio-respiratory sequelae.
- The hEDS coexists in 40-80% of cases depending on the series; check Beighton hypermobility before diagnosing isolated FM.
- The FM is rarely isolated : 89% comorbidity (IBS, migraine, depression, TMD, ME-CFS).
- Complex cases (PTSD, traumas) require psychological collaboration in addition to physiotherapy.
Bibliography chapter 6
- Ursini F, Ciaffi J, Mancarella L, et al. Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey. RMD Open. 2021;7(3):e001735. PMID 34426540
- Vincent A, Lahr BD, Wolfe F, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken). 2013;65(5):786-792. PMID 23203795.
- Coppens E, Van Wambeke P, Morlion B, et al. Prevalence and impact of childhood adversities and post-traumatic stress disorder in women with fibromyalgia and chronic widespread pain. Eur J Pain. 2017;21(9):1582-1590. PMID 28543929.
- Liptan GL. Fascia: A missing link in our understanding of the pathology of fibromyalgia. J Bodyw Mov Ther. 2010;14(1):3-12. PMID 20006283
- Fitzcharles MA, Cohen SP, Clauw DJ, et al. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397(10289):2098-2110. PMID 34062144
- Loggia ML, Chonde DB, Akeju O, et al. Evidence for brain glial activation in chronic pain patients. Brain. 2015;138(Pt 3):604-615. PMID 25582579
How do you apply these recommendations concretely in your practice?
When and to which other healthcare professionals should you refer?
Interprofessional referral is a fundamental clinical skill. It relies on two types of signals: red flags (organic pathology) and yellow flags (psychosocial factors).¹
The red flags (Finucane 2020) call for urgent or specialist medical advice:²
Red flags in the fibromyalgia context
- Very rapid onset of symptoms after age 60
- Overt inflammatory symptoms: morning stiffness > 60 min, joint swelling, redness
- Unexplained weight loss, night sweats, persistent fever
- Objective motor weakness or focal sensory deficits
- Unusual headaches, vomiting, visual disturbances
- Persistent bone pain, especially at night
- Known cancer, recent immunosuppressive treatment
- Total failure at 8-12 weeks of well-conducted management
The yellow flags of a psychosocial nature (Nicholas 2011) justify collaboration with a psychologist or psychotherapist:³
- Severe catastrophising (PCS > 30)
- Moderate to severe depression (PHQ-9 > 15)
- Severe anxiety (GAD-7 > 15)
- High kinesiophobia (Tampa Scale for Kinesiophobia > 40)
- Untreated traumatic history (high ACE score)
- Suicidal ideation (systematic screening - rate 2-3x higher in FM)
- Marked social isolation
Useful interprofessional network:
| Specialist | Reason for referral | Expected contribution |
|---|---|---|
| General practitioner | Coordination of the care pathway, prescription, follow-up | Central care coordinator |
| Rheumatologist | Diagnostic doubt, inflammatory comorbidity, failure of well-conducted management | Differential diagnosis, pharmacological optimisation |
| Pain centre | Severe, refractory, multi-comorbid FM | Intensive interdisciplinary management |
| Psychologist / CBT | Yellow flags, catastrophising, depression | CBT, ACT, MBSR |
| Psychiatrist | Severe depression, suicidal ideation, PTSD | Antidepressant treatment, EMDR |
| Adapted physical activity instructor | Independent return to sport | Long-term adapted physical activity |
| Dietitian | High BMI, suspected dysbiosis, IBS | Anti-inflammatory diet, FODMAP |
| Occupational therapist | Ergonomic difficulties at work/home | Adaptation, pacing, energy conservation |
| Social worker | Sick leave procedures, disability recognition | Administrative and social support |
How do you measure outcomes and overcome barriers to implementation?
Standardised outcome measurement is essential to steer treatment and justify effectiveness. The PROMs recommended for fibromyalgia:
| Tool | Domain assessed | Range | MCID |
|---|---|---|---|
| FIQR | Overall FM impact (function + symptoms + global) | 0-100 | ~14 points |
| NPRS / VAS | Pain intensity | 0-10 | ~1.5 points |
| PCS | Catastrophising | 0-52 | ~9 points |
| PHQ-9 | Depression | 0-27 | ~5 points |
| GAD-7 | Anxiety | 0-21 | ~4 points |
| PSQI | Sleep quality | 0-21 | ~3 points |
| TSK | Kinesiophobia (Tampa scale) | 17-68 | ~4 points |
| SF-36 / EQ-5D | Generic quality of life | 0-100 | variable |
Recommended frequency: initial assessment + reassessment at 4, 8, 12 weeks then at 6 and 12 months in follow-up.
Barriers to implementation (da Silva 2015):⁴
- Lack of time : adopt a fast workflow (questionnaires in the waiting room, automatic scoring)
- Lack of skills : continuing education (FIF-PL, DPC for physiotherapists)
- Lack of resources : use free platforms (rheumcalc.com for the FIQR, online scoring)
- Organisational inertia : start small (one PROM per patient, extend gradually)
- Patient resistance : explain how the scores help personalise follow-up
Effective strategies : audit and feedback, interactive training, integration into the electronic patient record, mentoring by clinical champions.⁵
Physio Learning - Stay informed
This article is part of the \"evidence-based clinical syntheses\" collection of the Physio Learning site. To go further, see our other syntheses on chronic pain, occupational ergonomics and multidisciplinary approaches.
Bibliography chapter 7
- Finucane LM, Downie A, Mercer C, et al. International Framework for Red Flags for Potential Serious Spinal Pathologies. J Orthop Sports Phys Ther. 2020;50(7):350-372. PMID 32438853
- Verhagen AP, Downie A, Maher CG, Koes BW. Most red flags for malignancy in low back pain guidelines lack empirical support: a systematic review. Pain. 2017;158(10):1860-1868. PMID 28708761
- Nicholas MK, Linton SJ, Watson PJ, Main CJ. Early identification and management of psychological risk factors (\"yellow flags\") in patients with low back pain: a reappraisal. Phys Ther. 2011;91(5):737-753. PMID 21451099
- da Silva TM, Costa Lda C, Garcia AN, et al. What do physical therapists think about evidence-based practice? A systematic review. Man Ther. 2015;20(3):388-401. PMID 25458142.
- Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2012;(6):CD000259. PMID 22696318
- Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11(4):R120. PMID 19664287
- Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. PMID 27377815
- Heymann RE, et al. Brazilian Society of Rheumatology's fibromyalgia treatment guidelines - part I: monitoring and non-pharmacological management. Adv Rheumatol. 2026;66(1):10. PMID 41546125





















